Consensus Korro Bio, Inc.

Equities

KRRO

US5009461089

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
62.93 ^USD	+7.52%		-5.71%	+31.30%

Apr. 24	Korro Bio Insider Bought Shares Worth $999,992, According to a Recent SEC Filing	MT
Apr. 24	Korro Bio Insider Bought Shares Worth $999,992, According to a Recent SEC Filing	MT

Evolution of the average Target Price on Korro Bio, Inc.

Price target over the last 5 years

History of analyst recommendation changes

0297e4869505b512dc0.Mo2IIOSibL9ljQeuUNaH6AHg3oBZjm7QazgbNFFvnno.Ar3OeonAHvsU1XfdfeOzjkCQjOsB9jy6H0h8QT5e_zdx38J6ldYIjlb7Xg~020e63020ce5e98f06f444a4225d7763

Analyst Recommendations on Korro Bio, Inc.

Korro Bio Insider Bought Shares Worth $999,992, According to a Recent SEC Filing	Apr. 24	MT
Korro Bio Insider Bought Shares Worth $999,992, According to a Recent SEC Filing	Apr. 24	MT
Korro Bio Insider Bought Shares Worth $999,992, According to a Recent SEC Filing	Apr. 24	MT
Korro Bio Insider Bought Shares Worth $999,992, According to a Recent SEC Filing	Apr. 24	MT
Korro Bio Insider Bought Shares Worth $999,992, According to a Recent SEC Filing	Apr. 24	MT
Korro Bio Insider Bought Shares Worth $999,992, According to a Recent SEC Filing	Apr. 24	MT
Korro Bio Insider Bought Shares Worth $999,992, According to a Recent SEC Filing	Apr. 24	MT
HC Wainwright Adjusts Korro Bio's Price Target to $115 From $100, Buy Rating Kept	Mar. 28	MT
RBC Boosts Price Target on Korro Bio to $90 From $70 on 'Increased Conviction for A1AT,' Keeps Outperform, Speculative Risk	Mar. 27	MT
BMO Capital Initiates Korro Bio With Outperform Rating, Price Target is $120	Feb. 27	MT
HC Wainwright Starts Korro Bio With Buy Rating, $100 Price Target	Dec. 04	MT
RBC Initiates Korro Bio at Outperform, Speculative Risk With $70 Price Target, Says Lead Program 'May Be Best-in-Class' for A1AT Protein	Nov. 29	MT
Piper Sandler Starts Coverage on Korro Bio with Overweight Rating, $180 Price Target	Nov. 10	MT
Baird Downgrades Frequency Therapeutics to Neutral From Outperform	23-09-26	MT
Chardan Downgrades Frequency Therapeutics to Neutral From Buy	23-02-15	MT
Baird Adjusts Frequency Therapeutics Price Target to $4 From $10, Maintains Outperform Rating	23-02-14	MT
Oppenheimer Downgrades Frequency Therapeutics to Perform From Outperform, Removes $8 Price Target	23-02-14	MT
Cowen Downgrades Frequency Therapeutics to Market Perform From Outperform	23-02-13	MT
Chardan Initiates Frequency Therapeutics With Buy Rating, $7 Price Target	22-12-08	MT
Oppenheimer Adjusts Frequency Therapeutics Price Target to $8 From $14, Maintains Outperform Rating	22-11-10	MT
Baird Starts Frequency Therapeutics at Outperform With $10 Price Target	22-11-02	MT
Goldman Sachs Adjusts Frequency Therapeutics' Price Target to $2 from $9, Keeps Neutral Rating	22-05-24	MT
B. Riley Lowers Frequency Therapeutics' PT to $10 from $17 to Reflect FX-322 Late-Stage Study Execution Timelines, OpEx Spend Trajectory; Keeps Buy Rating	22-03-23	MT
B. Riley Lowers Frequency Therapeutics' Price Target to $17 from $21 After Revising Cost Capital Assumptions, Keeps Buy Rating	22-01-24	MT
Oppenheimer Adjusts Frequency Therapeutics PT to $17 From $15, Maintains Outperform Rating	21-11-10	MT